 Daniel Sherbenou
Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 19 | 2025 | 125 | 8.260 |
Why?
| | Antibodies, Monoclonal | 9 | 2024 | 1368 | 2.280 |
Why?
| | Drug Resistance, Neoplasm | 8 | 2025 | 753 | 1.520 |
Why?
| | Immunoconjugates | 3 | 2020 | 104 | 1.510 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2025 | 118 | 1.360 |
Why?
| | Thalidomide | 3 | 2024 | 32 | 1.180 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2025 | 1560 | 1.160 |
Why?
| | Interferon Regulatory Factors | 2 | 2024 | 33 | 1.060 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2024 | 129 | 0.990 |
Why?
| | Fusion Proteins, bcr-abl | 4 | 2010 | 69 | 0.950 |
Why?
| | Immunoglobulin Light Chains | 1 | 2025 | 40 | 0.920 |
Why?
| | Osteolysis | 1 | 2025 | 18 | 0.920 |
Why?
| | Ikaros Transcription Factor | 1 | 2024 | 23 | 0.890 |
Why?
| | Protein Kinase Inhibitors | 7 | 2025 | 886 | 0.890 |
Why?
| | Piperazines | 5 | 2010 | 339 | 0.850 |
Why?
| | Pyrimidines | 5 | 2010 | 458 | 0.790 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2024 | 957 | 0.760 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2024 | 135 | 0.720 |
Why?
| | Hydrazines | 1 | 2021 | 34 | 0.710 |
Why?
| | Antineoplastic Agents | 5 | 2024 | 2045 | 0.710 |
Why?
| | Protein Synthesis Inhibitors | 1 | 2020 | 41 | 0.690 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2021 | 577 | 0.690 |
Why?
| | Membrane Cofactor Protein | 2 | 2018 | 13 | 0.690 |
Why?
| | ADP-ribosyl Cyclase 1 | 4 | 2024 | 37 | 0.670 |
Why?
| | Triazoles | 1 | 2021 | 148 | 0.640 |
Why?
| | Protein Biosynthesis | 1 | 2020 | 406 | 0.590 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 855 | 0.590 |
Why?
| | Antibodies, Neoplasm | 2 | 2018 | 34 | 0.570 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2017 | 181 | 0.470 |
Why?
| | Immunotherapy | 2 | 2017 | 596 | 0.430 |
Why?
| | Mutation | 4 | 2010 | 3706 | 0.420 |
Why?
| | Cell Line, Tumor | 7 | 2025 | 3185 | 0.420 |
Why?
| | Dexamethasone | 3 | 2021 | 352 | 0.410 |
Why?
| | Antibodies, Bispecific | 2 | 2024 | 49 | 0.340 |
Why?
| | src Homology Domains | 1 | 2010 | 37 | 0.340 |
Why?
| | Benzamides | 6 | 2018 | 203 | 0.320 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2025 | 1327 | 0.320 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2020 | 808 | 0.310 |
Why?
| | Imatinib Mesylate | 5 | 2010 | 75 | 0.310 |
Why?
| | Humans | 31 | 2025 | 129847 | 0.300 |
Why?
| | Transplantation Conditioning | 3 | 2020 | 166 | 0.290 |
Why?
| | Oligopeptides | 2 | 2021 | 260 | 0.290 |
Why?
| | Cord Blood Stem Cell Transplantation | 2 | 2020 | 99 | 0.290 |
Why?
| | Sequence Deletion | 1 | 2008 | 179 | 0.280 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2008 | 431 | 0.270 |
Why?
| | Mutant Proteins | 1 | 2007 | 100 | 0.260 |
Why?
| | Medical Oncology | 2 | 2025 | 268 | 0.250 |
Why?
| | B-Cell Maturation Antigen | 1 | 2024 | 9 | 0.220 |
Why?
| | Waldenstrom Macroglobulinemia | 1 | 2024 | 11 | 0.220 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2019 | 756 | 0.210 |
Why?
| | Bone Marrow | 3 | 2020 | 272 | 0.200 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 1 | 2025 | 217 | 0.200 |
Why?
| | Lymphoma, B-Cell | 1 | 2024 | 103 | 0.200 |
Why?
| | Lymphoma | 1 | 2024 | 198 | 0.200 |
Why?
| | Male | 13 | 2025 | 63759 | 0.200 |
Why?
| | Cell Proliferation | 5 | 2020 | 2378 | 0.200 |
Why?
| | Sequence Analysis, RNA | 1 | 2025 | 426 | 0.200 |
Why?
| | Single-Cell Analysis | 1 | 2025 | 274 | 0.190 |
Why?
| | Animals | 10 | 2025 | 35409 | 0.190 |
Why?
| | Mice | 7 | 2025 | 16983 | 0.180 |
Why?
| | Sulfonamides | 1 | 2025 | 497 | 0.180 |
Why?
| | Graft vs Host Disease | 2 | 2020 | 240 | 0.170 |
Why?
| | Neoplastic Stem Cells | 1 | 2025 | 378 | 0.170 |
Why?
| | Biomarkers, Tumor | 1 | 2007 | 1161 | 0.170 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2020 | 58 | 0.170 |
Why?
| | Proteasome Inhibitors | 1 | 2020 | 42 | 0.170 |
Why?
| | Heterografts | 1 | 2020 | 134 | 0.170 |
Why?
| | Drug Screening Assays, Antitumor | 1 | 2020 | 191 | 0.170 |
Why?
| | Primary Cell Culture | 1 | 2020 | 164 | 0.170 |
Why?
| | Transplantation, Homologous | 1 | 2021 | 402 | 0.160 |
Why?
| | Drug Synergism | 1 | 2020 | 370 | 0.160 |
Why?
| | Endoribonucleases | 1 | 2019 | 72 | 0.150 |
Why?
| | Aged | 9 | 2020 | 22107 | 0.150 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 931 | 0.150 |
Why?
| | Prognosis | 2 | 2025 | 3773 | 0.150 |
Why?
| | Thiotepa | 1 | 2018 | 20 | 0.150 |
Why?
| | Clinical Trials as Topic | 2 | 2017 | 1005 | 0.150 |
Why?
| | Melphalan | 1 | 2017 | 29 | 0.140 |
Why?
| | Neuroendocrine Tumors | 1 | 2018 | 99 | 0.140 |
Why?
| | Prostate | 1 | 2018 | 173 | 0.140 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2017 | 171 | 0.130 |
Why?
| | Flow Cytometry | 1 | 2020 | 1160 | 0.130 |
Why?
| | Treatment Outcome | 3 | 2021 | 10241 | 0.130 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2016 | 69 | 0.130 |
Why?
| | Protein Structure, Tertiary | 3 | 2007 | 844 | 0.130 |
Why?
| | Wnt Signaling Pathway | 1 | 2018 | 170 | 0.130 |
Why?
| | Female | 11 | 2024 | 68829 | 0.130 |
Why?
| | Salvage Therapy | 1 | 2017 | 136 | 0.130 |
Why?
| | Gene Dosage | 1 | 2016 | 143 | 0.130 |
Why?
| | Antigens, Neoplasm | 1 | 2018 | 308 | 0.120 |
Why?
| | Middle Aged | 8 | 2020 | 31177 | 0.120 |
Why?
| | Immunologic Factors | 1 | 2018 | 229 | 0.120 |
Why?
| | T-Lymphocytes | 1 | 2024 | 1937 | 0.120 |
Why?
| | Adult | 8 | 2020 | 35634 | 0.110 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 391 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1201 | 0.110 |
Why?
| | Aged, 80 and over | 4 | 2019 | 7066 | 0.100 |
Why?
| | Signal Transduction | 3 | 2020 | 4935 | 0.100 |
Why?
| | Adenocarcinoma | 1 | 2018 | 893 | 0.090 |
Why?
| | Recurrence | 3 | 2019 | 1013 | 0.090 |
Why?
| | Prostatic Neoplasms | 1 | 2018 | 999 | 0.090 |
Why?
| | Immunoblotting | 2 | 2008 | 306 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2023 | 14553 | 0.070 |
Why?
| | Follow-Up Studies | 2 | 2008 | 4896 | 0.070 |
Why?
| | Protein Kinases | 1 | 2010 | 318 | 0.070 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2008 | 39 | 0.070 |
Why?
| | Philadelphia Chromosome | 1 | 2007 | 18 | 0.070 |
Why?
| | Tyrosine | 1 | 2008 | 223 | 0.070 |
Why?
| | Cell Line | 2 | 2010 | 2780 | 0.070 |
Why?
| | Janus Kinase 2 | 1 | 2006 | 31 | 0.070 |
Why?
| | RNA, Neoplasm | 1 | 2007 | 82 | 0.070 |
Why?
| | Myeloproliferative Disorders | 1 | 2006 | 26 | 0.070 |
Why?
| | Codon | 1 | 2007 | 84 | 0.070 |
Why?
| | DNA, Neoplasm | 1 | 2007 | 154 | 0.060 |
Why?
| | Treatment Refusal | 1 | 2007 | 91 | 0.060 |
Why?
| | Remission Induction | 1 | 2007 | 274 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-abl | 1 | 2005 | 6 | 0.060 |
Why?
| | DNA Mutational Analysis | 1 | 2007 | 379 | 0.060 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 277 | 0.060 |
Why?
| | Models, Molecular | 1 | 2010 | 1488 | 0.060 |
Why?
| | Protein Conformation | 1 | 2008 | 861 | 0.060 |
Why?
| | Blast Crisis | 1 | 2025 | 33 | 0.060 |
Why?
| | src-Family Kinases | 1 | 2005 | 95 | 0.060 |
Why?
| | Mutation, Missense | 1 | 2006 | 316 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2007 | 954 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2007 | 585 | 0.060 |
Why?
| | Survival Analysis | 2 | 2018 | 1271 | 0.060 |
Why?
| | Phosphorylation | 1 | 2008 | 1716 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2008 | 4102 | 0.040 |
Why?
| | Cohort Studies | 1 | 2010 | 5444 | 0.040 |
Why?
| | X-Box Binding Protein 1 | 1 | 2019 | 9 | 0.040 |
Why?
| | Bortezomib | 1 | 2019 | 45 | 0.040 |
Why?
| | RNA, Messenger | 1 | 2007 | 2703 | 0.040 |
Why?
| | Unfolded Protein Response | 1 | 2019 | 53 | 0.040 |
Why?
| | Stevens-Johnson Syndrome | 1 | 2019 | 38 | 0.040 |
Why?
| | Young Adult | 2 | 2018 | 12467 | 0.040 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2019 | 101 | 0.040 |
Why?
| | Androstenes | 1 | 2018 | 17 | 0.040 |
Why?
| | Therapeutics | 1 | 2018 | 14 | 0.040 |
Why?
| | Macaca fascicularis | 1 | 2018 | 63 | 0.040 |
Why?
| | Antibody Affinity | 1 | 2018 | 59 | 0.040 |
Why?
| | Phenylthiohydantoin | 1 | 2018 | 41 | 0.040 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 21 | 0.040 |
Why?
| | Vidarabine | 1 | 2018 | 32 | 0.040 |
Why?
| | Low Density Lipoprotein Receptor-Related Protein-6 | 1 | 2018 | 4 | 0.040 |
Why?
| | Myocarditis | 1 | 2019 | 98 | 0.040 |
Why?
| | Whole-Body Irradiation | 1 | 2018 | 76 | 0.040 |
Why?
| | Fetal Blood | 1 | 2020 | 318 | 0.040 |
Why?
| | Nitriles | 1 | 2018 | 169 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 766 | 0.030 |
Why?
| | Wnt Proteins | 1 | 2018 | 126 | 0.030 |
Why?
| | Maximum Tolerated Dose | 1 | 2017 | 193 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 787 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2019 | 851 | 0.030 |
Why?
| | Transplantation, Autologous | 1 | 2017 | 213 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1199 | 0.030 |
Why?
| | beta Catenin | 1 | 2018 | 224 | 0.030 |
Why?
| | Recombinant Fusion Proteins | 1 | 2018 | 650 | 0.030 |
Why?
| | Biopsy | 1 | 2019 | 1089 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1872 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1690 | 0.030 |
Why?
| | Tumor Microenvironment | 1 | 2018 | 627 | 0.030 |
Why?
| | Hematopoietic Stem Cells | 2 | 2006 | 382 | 0.030 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2018 | 596 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2628 | 0.020 |
Why?
| | Biomarkers | 1 | 2019 | 3971 | 0.020 |
Why?
| | Hematopoiesis, Extramedullary | 1 | 2006 | 4 | 0.020 |
Why?
| | Polycythemia Vera | 1 | 2006 | 12 | 0.020 |
Why?
| | Polycythemia | 1 | 2006 | 21 | 0.020 |
Why?
| | Receptors, Erythropoietin | 1 | 2006 | 20 | 0.020 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2006 | 73 | 0.020 |
Why?
| | Clone Cells | 1 | 2006 | 262 | 0.020 |
Why?
| | Phosphotyrosine | 1 | 2005 | 36 | 0.020 |
Why?
| | Erythropoietin | 1 | 2006 | 88 | 0.020 |
Why?
| | Inhibitory Concentration 50 | 1 | 2005 | 86 | 0.020 |
Why?
| | Bone Marrow Cells | 1 | 2006 | 302 | 0.020 |
Why?
| | Time Factors | 2 | 2006 | 6550 | 0.020 |
Why?
| | Dasatinib | 1 | 2005 | 54 | 0.010 |
Why?
| | Thiazoles | 1 | 2005 | 118 | 0.010 |
Why?
| | Spleen | 1 | 2006 | 508 | 0.010 |
Why?
| | Point Mutation | 1 | 2005 | 224 | 0.010 |
Why?
| | Transfection | 1 | 2006 | 918 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2005 | 312 | 0.010 |
Why?
| | Fibrosis | 1 | 2006 | 526 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2006 | 1248 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 2005 | 482 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2006 | 1205 | 0.010 |
Why?
| | Stem Cells | 1 | 2005 | 578 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 2016 | 0.010 |
Why?
|
|
Sherbenou's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|